bladder cancer

envie a um amigo share this

New epigenetic biomarkers for the detection of bladder cancer in urine


Sara Monteiro-Reis (1), Ana Blanca (2), Joana Tedim-Moreira (1), Isa Carneiro (1,3), Diana Montezuma (1,3), Paula Monteiro (1,3), Jorge Oliveira (4), Luís Antunes (5), Rui Henrique (1,2,6), António Lopez-Beltran (7,8) e Carmen Jerónimo (1,6)

(1) Grupo de Epigenética e Biologia do Cancro – Centro de Investigação (CI-IPOP), Instituto Português de Oncologia do Porto Francisco Gentil EPE (IPO Porto), e Porto Comprehensive Cancer Center (P.CCC), Porto, Portugal;

Novos biomarcadores epigenéticos para deteção de cancro da bexiga em urina

Investigadores do Grupo de Epigenética e Biologia do Cancro do Centro de Investigação do IPO do Porto e da Universidade de Córdoba, em Espanha, publicaram recentemente na revista internacional Journal of Clinical Medicine os resultados de um dos seus mais recentes trabalhos, onde descrevem o desempenho de um novo teste não-invasivo que poderá ajudar na identificação de casos de cancro da bexiga numa população com outras patologias urinárias.

Bladder Cancer Translational Research Meeting: An unmet clinical and research need

Great Hall - Strand Campus, London, United Kingdom

 

29 March 2019

 

See more informations here: https://www.eacr.org/meeting/bladder-cancer-translational-research-meeting-an-unmet-clinical-and-research-need

Bladder Cancer Translational Research Meeting: An unmet clinical and research need

Great Hall - Strand Campus, London, United Kingdom

 

29 March 2019

 

See more informations here: https://www.eacr.org/meeting/bladder-cancer-translational-research-meeting-an-unmet-clinical-and-research-need

New insights about automatic bladder tumors detection

Bladder tumor is one of the leading causes of death, especially among men and its diagnosis is highly dependent on the interpreter’s experience of different exams. There is no doubt that the development of automatic detection systems will improve the detection accuracies of this pathology. Therefore, Nuno Freitas a Master student of Biomedical Engineering in University of Minho, oriented by Professor Carlos S.

NK Cell Immunotherapy: A New Approach to Bladder Cancer

Margarida Ferreira-Teixeira 1,2, Daniela Paiva-Oliveira 1,2, Belmiro Parada 1,3, Vera Alves 4, Vitor Sousa 5,6, Obinna Chijioke 7, Christian Münz 7, Flávio Reis 1,2, Paulo Rodrigues-Santos 4,8* and Célia Gomes 1,2*

Bladder cancer and urinary Schistosomiasis in Angola

Authors and Affiliations:

Monica C. Botelho,1,2 Jacinta Figueiredo,3 and Helena Alves1

1INSA, National Institute of Health Dr. Ricardo Jorge, Rua Alexandre Herculano, 321, 4000-055 Porto, Portugal
2IPATIMUP, Institute of Pathology and Molecular Immunology of the University of Porto, Portugal
3Department of Urology, Hospital Americo Boavida, Luanda, Angola
 

Abstract:

Metabolic alterations associated with bladder cancer progression were unveiled

A group of researchers from the Faculty of Health Sciences, University of Beira Interior (UBI-FCS), of the Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP) and of the School of Agriculture, Polytechnic Institute of Bragança (IPB) reported that the progression of bladder cancer from a less invasive stage to a highly invasive stage is accompanied by alterations in the metabolic phenotype of tumor cells. Since decades it is recognized that tumor cells have very specific metabolic properties associated with the malignant behavior of these cells.

Proteome profiling of urine with mass spectrometry approaches and bioinformatic tools allows an integrative perspective of the biological processes modulated by urothelial carcinoma

Using a well-established animal model of urothelial carcinoma, we performed urine proteome profiling from healthy animals and animals with urothelial carcinoma at two time-points of disease pathogenesis. Data analysis highlighted the biological processes involved in disease pathogenesis such as, for instance, response to selenium and to drugs, neutral lipid metabolism at earlier stages of disease, and inflammation, immune response and wound healing at advanced stages.

 

Authors and Affiliations:

Sialyl-Tn antigen (STn), which covers bladder cancer cells, contributes to the immune escape of these cells

Tumor cells often have aberrant post-translational modifications of their proteins. In bladder cancer, one of these modifications is the sialyl-Tn (STn) glycan, which is not expressed by normal cells and is highly expressed in high-grade bladder cancer cells. It is known that the immune response is affected by tumor cells, promoting tumor progression. However, little is known about the role of STn in the immune response and its influence on immune cells. Dendritic cells (DCs) play a crucial role in the immune response against tumor cells.